RFK Jr.’s vaccine committee votes against rarely used flu shot preservative, backs new RSV shot

The Centers for Disease Control and Prevention’s panel of vaccine advisers made a significant decision on Thursday, following the recent changes made by Health and Human Services Secretary Robert F. Kennedy Jr. Kennedy had dismissed the committee’s previous experts and replaced them with his own picks.

The committee approved updated recommendations for a new shot for respiratory syncytial virus (RSV) and advised Americans to avoid a small number of flu vaccines that contain the preservative thimerosal, despite evidence of its safety. These recommendations play a crucial role in shaping federal policies and programs related to vaccine access and coverage.

In addition to RSV and flu vaccines, the panel also discussed vaccines for COVID-19, measles, chikungunya, and anthrax, although no formal votes were taken on these vaccines. Kennedy’s new committee announced a review of all recommended pediatric vaccines, citing concerns about the cumulative impact of these shots on children. This review may lead to changes in recommendations for vaccines like hepatitis B and measles, given in early childhood.

However, the American Academy of Pediatrics (AAP) expressed concerns about these changes, warning against undermining trust in safe and effective immunizations. Dr. Martin Kulldorff, the panel’s chair, emphasized the importance of evidence-based medicine in making vaccine recommendations.

One notable decision by the panel was to recommend against flu vaccines containing thimerosal, a mercury-based preservative. While thimerosal is rarely used in flu vaccines in the U.S., the panel felt that its removal would enhance public confidence in vaccines. However, some experts questioned the need to revisit this issue, as scientific evidence supports the safety of thimerosal in vaccines.

The panel’s decision was influenced by a presentation from Lyn Redwood, a vocal critic of vaccine requirements. This move raised concerns among some panel members and outside groups, who felt that it could erode public trust in vaccines based on established scientific evidence.

The committee also voted on recommendations for an RSV vaccine for newborns, adding another option to prevent the disease. Despite concerns raised by some members about potential risks, the CDC and FDA did not find evidence of safety issues with the vaccine. The panel’s decisions highlight the importance of evidence-based medicine and rigorous review processes in shaping vaccine recommendations.

Overall, the panel’s decisions reflect a changing landscape in vaccine policy and highlight the need for transparency, scientific rigor, and public trust in the vaccination process. As the debate around vaccine recommendations continues, it is essential to prioritize the safety and efficacy of vaccines to protect public health.